Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4770-4775

  Hahnfeldt, Philip ^a   Panigrahy, Dipak ^b   Folkman, Judah ^b   Hlatky, Lynn ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ALGORITHM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTINEOPLASTIC AGENTS; COLLAGEN; CYCLOHEXANES; ENDOSTATINS; KINETICS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 0033213978     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
2. Folkman, J., Hahnfeldt, P., and Hlatky, L. The logic of anti-angiogenic gene therapy. In: T. Friedmann (ed.), The Development of Gene Therapy, pp. 1-17. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1998.
3. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 9: 267-282, 1990.
4. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13: 31-36, 1991.
5. Arap, W., Pasqualini, R., and Ruoslahti, E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol., 10: 560-565, 1998.
6. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
7. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
8. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin. A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
9. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
10. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (Lond.), 348: 555-557, 1990.
11. Figg, W. D., Pluda, J. M., Lush, R. M., Saville, M. W., Wyvill, K., Reed, E., and Yarchoan, R. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy, 17: 91-97, 1997.
12. Liotta, L. A., Saidel, G. M., and Kleinerman, J. Diffusion model of tumor vascularization and growth. Bull. Math. Biol., 39: 117-128, 1977.
13. Michelson, S., and Leith, J. T. Positive feedback and angiogenesis in tumor growth control. Bull. Math. Biol., 59: 233-254, 1997.
14. Balding, D., and McElwain, D. L. A mathematical model of tumour-induced capillary growth. J. Theor. Biol., 114: 53-73, 1985.
15. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Stellato, N., Bigelow, K., Heimann, R., Gately, S., Dhanabell, M., Soff, G. A., Sukhatmell, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in anti-tumour therapy. Nature (Lond.), 394: 287-291, 1998.
16. Teicher, B. A., Holden, S. A., Ara, G., Korbut, T., and Menon, K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother. Pharmacol., 38: 169-177, 1996.
17. Skehan, P. On the normality of growth dynamics of neoplasms in vivo: a data base analysis. Growth, 50: 496-515, 1986.
18. Spratt, J. S., Meyer, J. S., and Spratt, J. A. Rates of growth of human neoplasms: part II. J. Surg. Oncol., 61: 68-83, 1996.
19. Dewhirst, M. W. Concepts of oxygen transport at the microcirculatory level. Semin. Radiat. Oncol., 8: 143-150, 1998.
20. Hlatky, L., Hahnfeldt, P., Tsionou, C., and Coleman, C. N. VEGF. Environmental controls and effects in angiogenesis. A review. Br. J. Cancer, 74 (Suppl. XXVII): S151-S156, 1996.
21. Skipper, H. E. On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future). Bull. Math. Biol., 48: 253-278, 1986.
22. Prehn, R. T. Two competing influences that may explain concomitant tumor resistance. Cancer Res., 53: 3266-3269, 1993.